Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Oct;16(5):1179-1187.
doi: 10.1007/s12072-022-10396-7. Epub 2022 Aug 24.

Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial

Jian-Xu Li #  1 , Ting-Shi Su #  1 , Wen-Feng Gong  2 , Jian-Hong Zhong  2 , Liu-Ying Yan  3 , Jie Zhang  2 , Li-Qing Li  1 , Mei-Ling He  1 , Rui-Jun Zhang  1 , You-Qin Du  1 , Xiao-Ting Wang  1 , Shi-Xiong Liang  4 , Bang-De Xiang  5
Affiliations
Clinical Trial

Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial

Jian-Xu Li et al. Hepatol Int. 2022 Oct.

Abstract

Purpose: Stereotactic body radiotherapy (SBRT) may have significant immunomodulatory effects that enhance tumor response to immune checkpoint inhibitors. This phase 2 clinical trial was conducted to evaluate the safety and efficacy of combining palliative SBRT with camrelizumab (an anti-PD1 monoclonal antibody) in patients with unresectable hepatocellular carcinoma (uHCC).

Methods: Patients with uHCC, Child-Pugh A/B liver function, and at least one measurable lesion were enrolled between April 2020 and August 2022. Patients were administered 200 mg camrelizumab intravenously from the first day of palliative SBRT and then every 3 weeks. Palliative SBRT was delivered daily over five fractions per week, with a dose range of 30-50 Gy. The primary endpoints were objective response rate (ORR) and safety. This trial was registered at ClinicalTrials.gov (NCT04193696).

Results: Twenty-one patients were enrolled; the median radiation dose was 40 Gy, and the median number of cycles of camrelizumab was five. The ORR was 52.4%. After a median follow-up of 19.7 months, the median progression-free and overall survival were 5.8 and 14.2 months, respectively. The overall survival probability was 85.7% at 6 months, 76.2% at 9 months, and 59.9% at 12 months. All grade 3 treatment-related adverse events (TRAEs) occurred in five patients (23.8%) and were manageable. No grade 4/5 TRAEs were observed.

Conclusion: Palliative SBRT plus camrelizumab showed promising antitumor activity against uHCC. Toxicities were manageable with no unexpected safety issues. This study provides evidence of a new therapeutic method for the treatment of uHCC.

Keywords: Anti-PD1 monoclonal antibody; Camrelizumab; Clinical trial; Efficacy; Hepatocellular carcinoma; Objective response rate; Palliative; Safety; Stereotactic body radiotherapy; Unresectable.

PubMed Disclaimer

Conflict of interest statement

Jian-Xu Li, Ting-Shi Su, Wen-Feng Gong, Jian‑Hong Zhong, Liu-Ying Yan, Jie Zhang, Li‑Qing Li, Mei-Ling He, Rui-Jun Zhang, You-Qin Du, Xiao-Ting Wang, Shi-Xiong Liang, and Bang-De Xiang have no conflict of interest to declare that are relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Patient selection flow. HCC hepatocellular carcinoma, ICC intrahepatic cholangiocarcinoma
Fig. 2
Fig. 2
Kaplan–Meier analysis of overall and progression-free survival. a Overall and b progression-free survival for all patients, c overall and d progression-free survival for patients with Barcelona Clinic Liver Cancer stage C disease
Fig. 3
Fig. 3
Best percentage change from baseline in sums of diameters of target lesions by RECIST 1.1 (a) and mRECIST (b). CR complete response, PR partial response, SD stable disease, PD progressive disease
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48(1):103–109. doi: 10.1136/gut.48.1.103. - DOI - PMC - PubMed
    1. Zhong JH, Peng NF, You XM, et al. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: a real-world study. Oncotarget. 2017;8(11):18296–18302. doi: 10.18632/oncotarget.15433. - DOI - PMC - PubMed
    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi: 10.1056/NEJMoa0708857. - DOI - PubMed
    1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi: 10.1016/S0140-6736(18)30207-1. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data